Eledon Pharmaceuticals, Inc.

NASDAQ:ELDN

Biotechnology

Healthcare
$2.03 +2.84%

+$0.11 today

Market cap
$171.45M
Beta
0.97
P/E (TTM)
-5.5
EPS (TTM)
-$0.70
52W Low $1.35High $4.60

Volume 1.12M

Average 1.37M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$62.34M

FY 2025 · Annual

Investing Cash Flow

$10.79M

FY 2025 · Annual

Financing Cash Flow

$53.81M

FY 2025 · Annual

-59.7% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(34.51M)(87.97M)(116.54M)(36.18M)(45.62M)
Depreciation & Amortization195K373K374K359K313K
Deferred Income Tax(2.35M)00431K5K
Stock-Based Compensation7.9M8.15M6.55M13.12M10.45M
Change in Working Capital(152K)2.37M(4.92M)8.71M7.65M
Accounts Receivables00000
Inventory00000
Accounts Payables2.14M2.08M(2.6M)7.75M6.72M
Other Working Capital(2.3M)287K(2.32M)959K928K
Other Non-Cash Items048.65M75.01M(33.71M)(35.15M)
Operating Cash Flow(28.91M)(28.42M)(39.53M)(47.27M)(62.34M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00(78.29M)(156.13M)(161.13M)
Sales of Investments0033M85.82M171.93M
Other Investing Activities00000
Investing Cash Flow00(45.29M)(70.31M)10.79M
Debt Repayment00000
Common Stock Issued(449K)033.02M133.31M53.58M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities000215K0
Financing Cash Flow(449K)033.02M133.52M53.81M
Effect of Forex Changes00000
Net Change in Cash(29.36M)(28.42M)(51.8M)15.94M2.26M
Free Cash Flow(28.91M)(28.42M)(39.53M)(47.27M)(62.34M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$45.6M
+ D&A$313.0K
+ Stock-Based Comp$10.5M
+ Deferred Tax$5.0K
+ Working Capital$7.7M
- Other Non-Cash-$35.1M
= Operating Cash Flow-$62.3M
- Capex$0
= Free Cash Flow-$62.3M

Analysis

FY2025 free cash flow is -$62.3M. FCF conversion is 136.7% of net income. Operating cash flow was -$62.3M, with capex of $0. The largest bridge item is Other Non-Cash at -$35.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
SC 13G/ASC 13G/A filingOct 30, 2026
S-8S-8 filingSep 4, 2026
10-QQuarterly reportAug 13, 2026

Does ELDN generate free cash flow?

Eledon Pharmaceuticals, Inc. (ELDN) generated -$62.34M of free cash flow in fiscal 2025.

How much operating cash flow does ELDN produce?

Operating cash flow was -$62.34M, before capital expenditures of $0.00.